Administration of hydrogen-rich saline in mice with allogeneic hematopoietic stem-cell transplantation.
Lijuan Yuan, Xiaoping Chen, Liren Qian, Jianliang Shen, Jianming Cai · Medical science monitor : international medical journal of experimental and clinical research · 2015
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In BALB/c mice, forty percent of aGVHD mice with physiologic saline treatment survived to the 18 th day after BMT, and 90% of the mice with hydrogen-rich saline had survived ( Figure 1 ).This result suggests that hydrogen-rich saline can protect mice from lethal aGVHD. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in BALB/c mice. Forty percent of aGVHD mice with physiologic saline treatment survived to the 18 th day after BMT, and 90% of the mice with hydrogen-rich saline had survived ( Figure 1 ).This result suggests that hydrogen-rich saline can protect mice from lethal aGVHD.
What the Researchers Studied
The researchers studied BALB/c mice. The study used a preclinical animal experiment.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 30 days. Forty percent of aGVHD mice with physiologic saline treatment survived to the 18 th day after BMT, and 90% of the mice with hydrogen-rich saline had survived ( Figure 1 ).This result suggests that hydrogen-rich saline can protect mice from lethal aGVHD. Hydrogen, as a novel antioxidant, has been shown to selectively reduce the level of hydroxyl radicals and alleviate acute oxidative stress in many animal experiments. The normal spleen structure was destroyed in receptors and the number of lymphocyte cells in splenic white pulp was reduced ( Figure 3H ) in the physiologic saline group, and the change in spleen was reversed in the hydrogen-rich saline group ( Figure 3G ).
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was BALB/c mice. The reported sample size was 6. The study used a preclinical animal experiment. The reported treatment duration was 30 days.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.